Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...416417418419420421422423424425426...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Real World Assessment of Treatment Patterns and Outcomes Among Multiple Myeloma Patients across Different Risk Stratification Criteria in the United States: A Retrospective Cohort Study (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_3220;    
    Triplets were the most frequent treatment regimens (62% for R-ISS III and II, and 66% for R-ISS I; 59% for ISS III, and 65% for ISS II and I; 65% for HRCA and 61% for standard risk CA(SRCA) with proteasome inhibitors (PIs) / immunomodulatory agents (IMiDs) / dexamethasone being most common regimen across all the risk stratification criteria...Although a smaller proportion of patients have all the data collected needed for R-ISS classification, the consistent findings across treatment outcomes suggest that R-ISS is implementable in real world studies and has a greater discriminatory ability than ISS or HRCA alone. Overall, this study suggests that HR patients have relatively poor outcomes which calls for the study of risk-adapted implementation of novel therapies among this patient population in the US community practice settings.
  • ||||||||||  dexamethasone / Generic mfg.
    Bone Marrow Adipocytes Induce Metabolic Reprogramming of Multiple Myeloma Cells (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_3193;    
    In summary, we show that MM cells induce lipolysis in BMAd and that the released FFA are then taken up by MM cells through FATPs. Inhibition of either BMAd lipolysis or FFA transporter into MM cells could be a potential novel strategy to prevent MM progression.
  • ||||||||||  mezigdomide (CC-92480) / BMS
    Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_3192;    
    P1/2
    Taken together, these data demonstrate that POM and CC-92480 are potent immunomodulatory agents with enhanced induction of PBMC and NK mediated cell killing of MM tumor cells and activation of T and NK cells, at 100-fold lower concentrations of CC-92480 compared to POM. Additionally, we showed that combination with BTZ in preclinical assays and in the clinical setting did not antagonistically affect the immunostimulatory ability of POM or CC-92480.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Clinical Significance of Spatial Heterogeneity in Newly Diagnosed and Relapsed Multiple Myeloma (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_3186;    
    Our findings showing divergent results from MRD assessments in bone marrow and FL underline the critical role of whole-body imaging for follow-up of patients in remission. Sampling plasma cells solely from the IC limits the ability for complete clinical decision-making.
  • ||||||||||  dexamethasone / Generic mfg.
    Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_3172;    
    Second, we show that although IMiDs and GNE-781 induce an effective but transient response in vivo as single agents, the combination of the two drugs proved curative, with a progressive deepening of the anti-tumor response occurring even after therapy is discontinued. Ongoing experiments aim to determine how this drug combination, and other coactivator + transcription factor-targeting combinations, permanently disrupt myeloma-specific super-enhancers.
  • ||||||||||  dexamethasone / Generic mfg., cisplatin / Generic mfg.
    Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2952;    
    Based on the response to GDP therapy, 24 patients required second (N=20) or third (N=4) salvage regimens before ASCT (brentuximab vedotin [BV] alone or combination with bendamustine [N=16], pembrolizumab [N=9], and mini-BEAM [N=3])...Conclusion We propose a risk stratification model integrating a combination of DS and rMTV 41% on pre-ASCT PET and rel/ref status at time of progression, which allow discrimination of post-ASCT outcomes in patients with rel/ref cHL. The model may serve as a tool to facilitate risk-stratified treatment decisions.
  • ||||||||||  dexamethasone / Generic mfg.
    Genomics of Hyperleukocytic Acute Myeloid Leukemia (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2858;    
    The impact of midostaurin will be interesting to analyse in this setting. Inhibition of the RAS pathway could also be a valuable avenue.
  • ||||||||||  HPN217 / Harpoon Therap, AbbVie
    The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2744;    
    P1/2
    Herein, we describe translational studies to examine factors that may impact the therapeutic efficacy of HPN217, including the target BCMA, in membrane-bound or soluble form, and concomitant or combination therapeutics such as γ-secretase inhibitor (GSI) and dexamethasone...Interestingly, treatment of MM cell line RPMI8226 with the GSI LY-3039478 for 24 hours increased the cell surface expression of BCMA by 3.6 folds...On the other hand, Dex had limited negative effect. HPN217 in combination with approved and experimental MM therapeutics is being evaluated in the 3DTEBM and MM.1S-Luc models.
  • ||||||||||  dexamethasone / Generic mfg., nintedanib / Generic mfg.
    Targeting JAK2 Gene Rearrangements with a Novel Kinase Inhibitor in a Preclinical Model of Pediatric Acute Lymphoblastic Leukemia (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2739;    
    In combination with dexamethasone, we assessed a further decrease of viability between 10 to 95%...Importantly, combination of BIBF1120 and CHZ868 showed a synergistic effect (-45%, at IC50)...Indeed, active caspase 3 increased when ruxolitinib was given in combination with chloroquine, an autophagy inhibitor (+20% vs ruxolitinib alone, p<0.01)...CHZ868 is a promising candidate for treatment of BCP-ALL carrying JAK2 fusions, showing high efficacy and specificity, both ex vivo and in vivo . Further studies will include combination with standard chemotherapy drugs with the aim to maintain its efficacy by reducing the intensity and toxicity of chemotherapy.
  • ||||||||||  dexamethasone / Generic mfg., apixaban / Generic mfg.
    Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2619;    
    The incidence of major bleeding or CRNMB was 5%. Hypofibrinogenemia, acquired AT deficiency due to ASP, was seen between days 7-21 after using ASP (figure 1 & 2) and recovered subsequently.
  • ||||||||||  dexamethasone / Generic mfg.
    Sickle Cell Disease and COVID-19 Infection: A Single-Center Experience (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2527;    
    We found a mortality rate of 3.9% in our single-center study of patients with SCD and CO19 infection. This mortality rate is lower than other published experiences in patients with SCD and CO19 infection.
  • ||||||||||  dexamethasone / Generic mfg.
    The Glucocorticoid Receptor-Dependent Stress Response in Human Erythropoiesis Is BCL11A-Dependent (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2478;    
    Extrapolations from data in mouse models and from human erythroid cells expanded ex vivo with the glucocorticoid receptor (GR) agonist Dexamethasone (Dex), suggest that GR plays an important role in the regulation of stress erythropoiesis 1...References 1) Varricchio et al Am J Blood Res . 2014;4:53; 2) Funnell et al Blood 2015; 126:89; 3) Ashley et al JCI 2020;130:2097; 4) Zhang L et al Nature 2013;499:92; 5) Lee et al Nature 2015;522:474; 6) Heideveld et al Haematologica 2015; 100:1396; 7) Xiang et al Blood 2015;125:1803.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    ASH Poster Walk on Geriatric Hematology: Selecting the Right Treatment for the Patient, Not Just the Disease () -  Nov 5, 2021 - Abstract #ASH2021ASH_2447;    
    The ASH Poster Walk on Geriatric Hematology will aggregate these diverse abstracts into a single discussion, allowing key opinion leaders to provide context on the current state of the art in geriatric hematology, covering topics including elderly-specific therapeutic trials, frailty and geriatric assessment. The following abstracts will be featured in this session: Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial) , Matthias Stellijes Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities – Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY) , Victor Jimenez-Yuste The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors , Kunhwa Kim Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02) , Slavisa Ninkovic Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial , Abi Vijenthira A Cross-Sectional Analysis of County-Level Social Vulnerability and Physical Frailty Among Adults with Hematological Malignancies , Shakira Grant
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, PRGN-3006 / Precigen, PRGN-3005 / Precigen
    Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes (GWCC - Georgia Ballroom 1-3) -  Nov 5, 2021 - Abstract #ASH2021ASH_2334;    
    P1
    Ps receive PRGN-3006 infusion without (Cohort 1) or with lymphodepletion (fludarabine 30mg/m 2 and cyclophosphamide 500mg/m 2 days -5 to -3; Cohort 2)...Pts were heavily pre-treated with a median of 3 prior regimens (1-7), with 93% and 80% of pts being r/r to a HMA + venetoclax or intensive chemotherapy, respectively...Cytokine release syndrome (CRS) occurred in 47% of pts (n=7; G1 in 5 pts) with only 1 transient grade 3 event (DL 1, Cohort 1) that resolved in < 24 hours with tocilizumab and dexamethasone...In the setting of mbIL15, there has been a dose-dependent robust expansion and durable persistence of PRGN-3006 with encouraging responses (50%) in patients treated following lymphodepletion. Enrollment is ongoing to DL4, and updated safety, efficacy, PK/PD and cytokine data to be presented.